Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use

• US 7,517,520 B2
• Filed: 03/25/2004
• Issued: 04/14/2009
• Est. Priority Date: 03/26/2003
• Status: Active Grant

• Current Assignee: Kuros Company Limited
• Original Assignee: Cytos Biotechnology AG (Kuros Biosciences Ltd.)
• Inventors: Maurer, Patrik, Bachmann, Martin F., Meijerink, Edwin, Schwarz, Katrin, Proba, Karl G., Manolova, Vania, Cornelius, Andreas
• Primary Examiner(s): LI, QIAN JANICE
• Application Number:
  US10/550,518
• Publication Number:
  US 20060251677A1
• Time in Patent Office: 1,846 Days
• Field of Search: None
• US Class Current: 424/93.2
• CPC Class Codes: A61K 2039/5258 Virus-like particles
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 2039/6075 Viral proteins
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/21 Retroviridae, e.g. equine infectious anemia virus
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 15/117 Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• CPC Class Codes: C12N 2310/18 acting by a non-sequence specific mechanism other than C12N2310/16 or C12N2310/17
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2730/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2730/10123 Virus like particles [VLP]
• CPC Class Codes: C12N 2730/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16222 : New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2740/16234 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2760/10022 : New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2760/10034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2795/18122 : New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2795/18123 : Virus like particles [VLP]
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

Claims

1. A composition comprising:

(a) a virus-like particle; and

(b) at least one immunostimulatory substance;

wherein said immunostimulatory substance is packaged into said virus-like particle, and wherein said immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of said unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, and wherein said palindromic sequence is flanked at its 3′

-terminus and at its 5′

-terminus by less than 10 guanosine entities.

2. The composition of claim 1 further comprising at least one antigen or antigenic determinant, wherein said antigen or antigenic determinant is bound to said virus-like particle.

3. The composition of claim 2, wherein said antigen or antigenic determinant is bound to said virus-like particle by at least one non-peptide covalent bond.

4. The composition of claim 2, wherein said virus-like particle comprises at least one first attachment site and wherein said antigen or antigenic determinant further comprises at least one second attachment site being selected from the group consisting of:

(a) an attachment site not naturally occurring with said antigen or antigenic determinant; and

(b) an attachment site naturally occurring with said antigen or antigenic determinant;

and wherein said binding of said antigen or antigenic determinant to said virus-like particle is effected through association between said first attachment site and said second attachment site, wherein said association is through at least one non-peptide covalent bond; and

wherein said antigen or antigenic determinant and said virus-like particle interact through said association to form an ordered and repetitive antigen array.

5. The composition of claim 4, wherein said first attachment site comprises an amino group.

6. The composition of claim 4, wherein said second attachment site comprises a sulfhydryl group.

7. The composition of claim 4, wherein said first attachment site is an amino group and said second attachment site is a sulfhydryl group.

8. The composition of claim 2, wherein said antigen is derived from the group consisting of:

(a) viruses;

(b) bacteria;

(c) parasites;

(d) prions;

(e) tumors;

(f) self-molecules;

(g) non-peptidic hapten molecules

(h) allergens; and

(i) hormones.

9. The composition of claim 2, wherein said antigen is a tumor antigen, wherein said tumor antigen is selected from the group consisting of:

(a) Her2;

(b) GD2;

(c) EGF-R;

(d) CEA;

(e) CD52;

(f) CD21;

(g) human melanoma protein gp100;

(h) human melanoma protein melan-A/MART-1;

(i) tyrosinase;

(j) NA17-A nt protein;

(k) MAGE-3 protein;

(l) p53 protein;

(m) HPV16 E7 protein;

(n) human melanoma MelanA peptide;

(o) human melanoma MelanA peptide analogue; and

(p) antigenic fragments of any of the tumor antigens from (a) to (o).

10. The composition of claim 2, wherein said antigen is bound to said virus-like particle by way of a linking sequence.

11. The composition of claim 2, wherein said antigen comprises a cytotoxic T cell epitope, a Th cell epitope or a combination of at least two of said epitopes, wherein said at least two epitopes are bound directly or by way of a linking sequence, and wherein said cytotoxic T cell epitope is a viral or a tumor cytotoxic T cell epitope.

12. The composition of claim 1, wherein said unmethylated CpG-containing oligonucleotide comprises 10 to 30 nucleotides.

13. The composition of claim 1, wherein said palindromic sequence is GACGATCGTC (SEQ ID NO:

1).

14. The composition of claim 1, wherein said palindromic sequence is flanked at its 5′

-terminus by at least 3 and at most 9 guanosine entities and wherein said palindromic sequence is flanked at its 3′

-terminus by at least 6 and at most 9 guanosine entities.

15. The composition of claim 13, wherein said unmethylated CpG-containing oligonucleotide has a nucleic acid sequence selected from

(a) GGGGACGATCGTCGGGGGG (SEQ ID NO:

2);

(b) GGGGGACGATCGTCGGGGGG (SEQ ID NO;

3);

(c) GGGGGGACGATCGTCGGGGGG (SEQ ID NO;

4);

(d) GGGGGGGACGATCGTCGGGGGG (SEQ ID NO;

5);

(e) GGGGGGGGACGATCGTCGGGGGGG (SEQ ID NO;

6);

(f) GGGGGGGGGACGATCGTCGGGGGGGG (SEQ ID NO;

7);

(g) GGGGGGGGGGACGATCGTCGGGGGGGGG (SEQ ID NO;

8); and

(h) GGGGGGCGACGACGATCGTCGTCGGGGGGG (SEQ TD NO;

9).

16. The composition of claim 1, wherein said virus-like particle comprises recombinant proteins of an RNA-phage, wherein said RNA-phage is selected from the group consisting of:

(a) bacteriophage Qβ

;

(b) bacteriophage R17;

(c) bacteriophage fr;

(d) bacteriophage GA;

(e) bacteriophage SP;

(f) bacteriophage MS2;

(g) bacteriophage M11;

(h) bacteriophage MX1;

(i) bacteriophage NL95;

(j) bacteriophage f2;

(k) bacteriophage PP7; and

(l) bacteriophage AP205.

17. The composition of claim 1, wherein said virus-like particle comprises recombinant proteins of bacteriophage Qβ

or bacteriophage AP205.

18. A vaccine comprising an immunologically effective amount of the composition of claim 1 together with a pharmaceutically acceptable diluent, carrier or excipient.

19. The composition of claim 2, wherein said antigen is an HIV polypeptide.

20. The composition of claim 2, wherein said antigen is a recombinant HIV polypeptide.

21. The composition of claim 2, wherein said antigen is HIV antigen gp 160 or an antigenic fragment thereof.

22. The composition of claim 2, wherein said antigen is HIV antigen gp 140 or an antigenic fragment thereof.

23. The composition of claim 2, wherein said antigen is HIV antigen gp 140.

24. The composition of claim 2, wherein said antigen or antigenic determinant is bound to said virus-like particle by at least one peptide bond.

25. The composition of claim 4, wherein said palindromic sequence is flanked at its 5′

-terminus by at least 3 and at most 9 guanosine entities and wherein said palindromic sequence is flanked at its 3′

-terminus by at least 6 and at most 9 guanosine entities.

26. The composition of claim 2, wherein said antigen is a tumor antigen.

27. The composition of claim 26, wherein said tumor antigen is derived from breast cancer.

28. The composition of claim 26, wherein said tumor antigen is a recombinant polypeptide of breast cancer cells.

29. The composition of claim 2, wherein said antigen is Her2 or an antigenic fragment thereof.

30. The composition of claim 2, wherein said antigen is Her2.

31. The composition of claim 2, wherein said antigen is a human melanoma MelanA/MART-1 peptide analogue.

32. The composition of claim 2, wherein said antigen consists of the sequence ELAGIGILTV (SEQ ID NO:

35).

33. The composition of claim 2, wherein said antigen is a viral antigen.

34. The composition of claim 2, wherein said antigen is derived from a Pneumovirus, wherein said Pneumovirus is the respiratory syncytial virus (RSV).

35. The composition of claim 2, wherein said antigen is a recombinant polypeptide of Influenza virus.

36. The composition of claim 2, wherein said antigen is the influenza antigen M2 protein or an antigenic fragment thereof.

37. The composition of claim 36, wherein said antigen is fused to said virus-like particle, and wherein said virus-like particle is a virus-like particle of an RNA-phage AP205.

38. The composition of claim 2, wherein said antigen is the influenza antigen hemagglutinin or an antigenic fragment thereof.

39. The composition of claim 38, wherein said antigen is fused to said virus-like particle, and wherein said virus-like particle is a virus-like particle of an RNA-phage AP205.

40. The composition of claim 2, wherein said antigen is an allergen.

41. The composition of claim 2, wherein said antigen is Bet v I or an antigenic fragment thereof.

42. The composition of claim 2, wherein said antigen is Bet v I.

43. The composition of claim 1, wherein said unmethylated CpG-containing oligonucleotide consists of the nucleic acid sequence GGGGGGGGGACGATCGTCGGGGGGGG (SEQ ID NO:

6).

44. The composition of claim 1, wherein said unmethylated CpG-containing oligonucleotide consists of the nucleic acid sequence GGGGGGGGGGACGATCGTCGGGGGGGGG (SEQ ID NO:

7).

45. The composition of claim 1, wherein said virus-like particle is a virus-like particle of an RNA-phage.

46. The composition of claim 45, wherein said RNA-phage is bacteriophage Qβ

.

47. The composition of claim 46, wherein said palindromic sequence is flanked at its 5′

-terminus by at least 3 and at most 9 guanosine entities and wherein said palindromic sequence is flanked at its 3′

-terminus by at least 6 and at most 9 guanosine entities.

48. The composition of claim 45, wherein said RNA-phage is bacteriophage AP205.

49. The composition of claim 48, wherein said palindromic sequence is flanked at its 5′

-terminus by at least 3 and at most 9 guanosine entities and wherein said palindromic sequence is flanked at its 3′

-terminus by at least 6 and at most 9 guanosine entities.

50. The composition of claim 1, wherein said virus-like particle comprises recombinant proteins, and wherein said recombinant proteins consist of coat proteins consisting of the amino acid sequence of SEQ ID NO:

10.